Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
Bio-IT World May 19, 2004 Barbara Depompa	From Corn Belt to Bio Belt The Danforth Center in St. Louis attempts to lay the foundation for the local chamber of commerce's efforts to promote the region as a world-class location for plant and life science research.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
National Real Estate Investor December 1, 2005	In Progress: The Bottle District The 900,000 sq. ft. development located on 18 acres will be the first-of-its-kind entertainment venue in St. Louis and will include daytime attractions for the whole family.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool May 14, 2008 Brian Lawler	Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.
Fast Company June 2004 Bill Breen	The Thrill of Defeat Want to know how to motivate people to take on tough odds? Ask the folks in Pfizer's labs, where managing failure is a fine art and superhuman persistence an everyday habit.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
CRM October 2011	Marketing Muscle Extends to Satellite Hospital in Sullivan Although Missouri Baptist lies in the heart of suburban St. Louis, the marketing team devotes considerable time -- about 80 hours per month -- to its satellite hospital in Sullivan, Mo.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
CIO October 28, 2011 Kim S. Nash	Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool December 18, 2007 Jeff Hwang	No Room at the Inn Ameristar Casino announces that the opening of the St. Charles 400-room all-suite hotel and spa -- originally scheduled for this month in St. Louis -- would be delayed in its entirety into next year.
The Motley Fool October 1, 2008 Brian Orelli	Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool June 20, 2011 Luke Timmerman	Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario?
Registered Rep. June 28, 2007 Christina Mucciolo	Wachovia Securities to Make New Home in St. Louis Federal Antitrust regulators approved Wachovia Corp.'s acquisition of A.G. Edwards. The deal is expected to close in the fourth quarter, most likely in October.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
Bio-IT World November 14, 2003 John Dodge	Pfizer's Man with the R&D Plan As Pfizer senior vice president, science and technology, Peter B. Corr oversees $7.1 billion in annual research and development spending, the biggest private R&D budget in the world. In this interview, Corr talks about IT, clinical trials, and his $7-billion budget.
Sports Central March 21, 2004 Josie Lemieux	The Little Engine That Could St. Louis, Cory Stillman, Vinny Lecavalier, and Brad Richards don't play for the wildest, richest, and most influential team in the NHL, but the show is worth it. Hockey seems good these days in Florida.
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
The Motley Fool April 7, 2009 Brian Orelli	Pfizer's Mind Meld Pfizer has a plan now for its structure after its acquisition of Wyeth -- including keeping eight senior executives from its new purchase.
National Real Estate Investor January 1, 2006	Deals & Projects Harbor Group International has acquired the 12-story Deloitte Building in downtown St. Louis... Howard California Properties has paid $2.3 million for one of the last raw land parcels available... etc.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
National Real Estate Investor April 1, 2003 Margaret Jackson	Downtown Renaissance With the February opening of a $270 million convention center hotel complex, downtown St. Louis has received nearly $1.4 billion in public and private investment since 1998 -- the largest investment ever in the city over such a brief period.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
Pharmaceutical Executive August 1, 2011 William Looney	Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation.
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
Sports Illustrated March 7, 2002 Peter King	Dropping the ball Cris Carter should have stayed the course with the Rams...
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
National Real Estate Investor September 1, 2005	Deals & Projects Clayco of St. Louis has been selected as general contractor and construction manager... R.J. Brunelli of Old Bridge, N.J. announced that it brokered $40 million in real estate... etc.
The Motley Fool November 21, 2007 Brian Lawler	Pfizer Finds an Old Friend Pfizer announces its purchase of partner Coley Pharmaceutical, securing Coley's novel technology for targeting toll-like receptors.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool July 21, 2006 Jeff Hwang	Reevaluating Ameristar: St. Louis, Part 2 Investors should remain cautiously optimistic about Ameristar's prospects in the dynamic St. Louis market. If history is any indication, the effect the competition will have on the two biggest players in the market -- Ameristar and Harrah's -- will be slighter than one might expect.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.